ApicHope Pharmaceutical Group Co., Ltd.

ApicHope Pharmaceutical Group Co., Ltd. is a biopharmaceutical enterprise founded in 2002 and listed on the Shenzhen Stock Exchange in November 2017. Headquartered in Guangzhou International Bio-Island, the company focuses on drug innovation research and development (R&D), production, and sales, particularly in pediatric medicines and chronic diseases. ApicHope is recognized as one of the top companies in China for its comprehensive strength in chemical drug R&D. The company's operations encompass a wide range of business lines, including the development of innovative drugs for pediatric and chronic diseases. ApicHope has established two innovative R&D platforms dedicated to these areas, with a robust pipeline of over 61 projects and 200 drug registrations. Its manufacturing capabilities are supported by advanced facilities that comply with GMP, EU, and FDA regulations, enabling the production of innovative drugs and high-end generics. ApicHope is committed to enhancing its R&D capabilities and maintaining a diverse product portfolio to address various medical needs, particularly in children's health and chronic disease management.

1. Well-established innovative R&D system and continuously improved innovation and transformation capabilities The company adheres to the concept of global development and has a complete R&D organization, including an innovative drug research center, high-end preparation research center, comprehensive research center, and other research institutions. The direction of R&D includes first-in-class drugs with source innovation and covers products with similar high-efficiency, high-end dosage forms, and difficult imitation products. 1.1 Advantages of R&D platform Relying on comprehensive basic research platforms undertaken by the company such as the National Enterprise Technology Center, the National Postdoctoral WorkStation, the Guangdong Pediatric Engineering Laboratory, the Guangdong Enterprise Technology Center, and the Guangdong Biochemical Engineering Research Center, the company has established two innovative technology R&D platforms for children's medicines and chronic disease medicines the company possesses the R&D and operational capabilities of the whole life cycle from drug molecule design, screening, clinical transformation to product industrialization, focusing on the R&D of innovative drugs with better quality and efficacy. 1.2 Advantages of Innovation and Transformation Intellectual property (IP) plays an important role in the transformation of scientific and technological achievements into real-life productivity. The Company has continued to improve the establishment of an IP and results transformation service system and has continued to incubate a large number of scientific and technological achievements and related IP, taking multiple measures to enhance the ability to manage, create, protect and apply IP. 1.3 Advantages of R&D team ApicHope, insisting on R&D and innovation, creating high-quality products and large variety, keeping a clear strategy and direction, has outstanding R&D efficiency and innovation results. The company has well-established R&D institutions, including an innovative drug R&D center, advanced formulation research center, comprehensive R&D center, and other research institutions, which can meet the needs of overseas scientists' needs to construct innovation platforms and develop multi-technology platforms. At present, the key core technology members hold company stocks/options through equity incentives, and the R&D team is stable. In the future, the company will continue to increase investment in R&D, optimize the innovation mechanism, expand the R&D technical team, further enhance the innovation and R&D capabilities, continuously consolidate the core product line and core competitiveness, and promote sustainable, stable and healthy development. 2. Diverse marketed portfolio and robust R&D pipeline in pediatric & chronic disease therapeutics Relying on a comprehensive innovative R&D system and years of market experience, the company has formed a broad coverage, focused, and laddered product structure. In the field of pediatric drugs, the company has a reasonable product structure, a complete range of products, a wide spectrum of diseases, and a rich product reserve, which has strong sustainable development potential. The company has 27 pediatric drug registration approvals, covering respiratory, digestive, skin, and other diseases, covering the entire age group of children and adolescents, and can be used to treat common diseases with urgent clinical needs, such as influenza, colds, infectious diseases, functional dyspepsia, HFMD and eczema in children. The Company has 67 registered approvals for chronic disease drugs, covering the treatment of cardiovascular and cerebrovascular diseases, kidney diseases, digestive system diseases, liver diseases, and other disease areas, and several products have been listed in the National Essential Drug List and the National Medical Insurance Catalogue. The chronic disease drug pipeline includes 25 projects, such as the globally innovative drug AR882 and the small-molecule agonist APH01727 tablets, most of which have exclusive patents and unique therapeutic advantages. The company's innovative drug AR882 for hyperuricemia and gout has been conducted in international multi-center Phase II 2b clinical trials with remarkable efficacy results. And the global multi-center phase III clinical trial has started. In August 2024, AR882 was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of visible tophi in clinical gout patients. 3. Academic-led branding capabilities and a multi-dimensional marketing network system Marketing capability is the foundation of the company's development and expansion. Currently, the Company's marketing network covers 31 provincial administrative regions. With the deepening construction of the marketing network system, the Company's market coverage and the number of products on sale have gradually increased, driving the steady growth of sales of the Company's pharmaceutical manufacturing products. In addition, there are also the Company's OTC Pharmaceutical Marketing Centre and ApicHope Pharmacy, which vigorously explore new retail channels such as chain KA, internet marketing and third terminal market to create a multi-dimensional marketing network, synergize and increase efficiency to meet the diversified market needs of consumers and enhance the Company's terminal market coverage level and core competitiveness. 4. Digital & Intelligent Operations Management Platform with Value-Driven Integrated Management Capabilities The core management team members have many years of management experience in the pharmaceutical industry, with high sensitivity and foresight to market and policy development trends, strong learning ability and innovation spirit, and can manage the company's strategic development. The management team is mature, stable, professional, and able to follow the pharmaceutical industry's development trend and ensure the enterprise's healthy and sustainable development. The company insists on an open and transparent talent selection mechanism to provide a broad career platform for outstanding talents. The company has a perfect management mechanism and authorization system, and its operation and management are coordinated and efficient. Share the company's interests by setting up short-term and long-term incentive plans from various aspects together with a systematic performance management strategy. We provide equity incentives to the management team and key talent, and a promising career platform for value realization. The company has established a hybrid cloud-based IT and intelligent platform, comprehensively advancing enterprise information system development to achieve closed-loop smart management across R&D, production, and sales. This provides a robust foundation for digitalized operations and data-driven decision-making.